Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway

This study investigated the effect of acylated synthetic ghrelin (AG) on the survival and proliferation of human chemosensitive ovarian cancer cells (A2780) and explored some mechanisms of action with a focus on the p53 apoptotic pathway and PI3K/Akt and NF-κB survival pathways. Human A2780 ovarian...

Full description

Saved in:
Bibliographic Details
Main Authors: Attalla Farag El-kott, Ali A. Shati, Mohammed Ali Al-kahtani, Sultan Alqahtani
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Analytical Cellular Pathology
Online Access:http://dx.doi.org/10.1155/2019/9627810
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832556411766177792
author Attalla Farag El-kott
Ali A. Shati
Mohammed Ali Al-kahtani
Sultan Alqahtani
author_facet Attalla Farag El-kott
Ali A. Shati
Mohammed Ali Al-kahtani
Sultan Alqahtani
author_sort Attalla Farag El-kott
collection DOAJ
description This study investigated the effect of acylated synthetic ghrelin (AG) on the survival and proliferation of human chemosensitive ovarian cancer cells (A2780) and explored some mechanisms of action with a focus on the p53 apoptotic pathway and PI3K/Akt and NF-κB survival pathways. Human A2780 ovarian cancer cells were cultured with or without AG treatment in the presence or absence of cisplatin. In some cases, cisplatin+AG-treated cells were pre-incubated either with [D-Lys3]-GHRP-6, a ghrelin receptor antagonist, or with LY294002, a PI3K inhibitor. mRNA of ghrelin receptors(GHS-R1a and GHS-R1b), as well as, protein levels of GHS-R1a, were expressed abundantly in A2780 cells. AG treatment did not affect the mRNA and protein levels of GHS-R1a and GHS-R1b in both control and Cis-treated cells. However, while AG treatment had no effect on control cell viability, it significantly increased cell viability and proliferation and inhibited cell death in Cis-treated cells. In both control and Cis-treated cells, AG treatment significantly increased PI3K/Akt/mTOR signaling and enhanced the nuclear accumulation of NF-κB. Concomitantly, in both control and Cis-treated cells, AG significantly lowered the protein levels of p53, p-p53 (Ser16), PUMA, cytochrome C, and cleaved caspase-3. Interestingly, pre-incubating the cells with either [D-Lys3]-GHRP-6 or LY294002 completely abolished the above-mentioned effect of AG in both control and Cis-treated cells. In conclusion, the findings of this study show that AG promotes cell survival of the OC cells and renders them resistat to Cis therapy, an effect that is mediated by the activation of PI3K/Akt/mTOR and activation of NF-κB, and requires GHS-R1a.
format Article
id doaj-art-ccc2f108db554204b01dfedd3e370131
institution Kabale University
issn 2210-7177
2210-7185
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Analytical Cellular Pathology
spelling doaj-art-ccc2f108db554204b01dfedd3e3701312025-02-03T05:45:32ZengWileyAnalytical Cellular Pathology2210-71772210-71852019-01-01201910.1155/2019/96278109627810Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival PathwayAttalla Farag El-kott0Ali A. Shati1Mohammed Ali Al-kahtani2Sultan Alqahtani3Biology Department, College of Science, King Khalid University, Abha, Saudi ArabiaBiology Department, College of Science, King Khalid University, Abha, Saudi ArabiaBiology Department, College of Science, King Khalid University, Abha, Saudi ArabiaDepartment of Basic Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi ArabiaThis study investigated the effect of acylated synthetic ghrelin (AG) on the survival and proliferation of human chemosensitive ovarian cancer cells (A2780) and explored some mechanisms of action with a focus on the p53 apoptotic pathway and PI3K/Akt and NF-κB survival pathways. Human A2780 ovarian cancer cells were cultured with or without AG treatment in the presence or absence of cisplatin. In some cases, cisplatin+AG-treated cells were pre-incubated either with [D-Lys3]-GHRP-6, a ghrelin receptor antagonist, or with LY294002, a PI3K inhibitor. mRNA of ghrelin receptors(GHS-R1a and GHS-R1b), as well as, protein levels of GHS-R1a, were expressed abundantly in A2780 cells. AG treatment did not affect the mRNA and protein levels of GHS-R1a and GHS-R1b in both control and Cis-treated cells. However, while AG treatment had no effect on control cell viability, it significantly increased cell viability and proliferation and inhibited cell death in Cis-treated cells. In both control and Cis-treated cells, AG treatment significantly increased PI3K/Akt/mTOR signaling and enhanced the nuclear accumulation of NF-κB. Concomitantly, in both control and Cis-treated cells, AG significantly lowered the protein levels of p53, p-p53 (Ser16), PUMA, cytochrome C, and cleaved caspase-3. Interestingly, pre-incubating the cells with either [D-Lys3]-GHRP-6 or LY294002 completely abolished the above-mentioned effect of AG in both control and Cis-treated cells. In conclusion, the findings of this study show that AG promotes cell survival of the OC cells and renders them resistat to Cis therapy, an effect that is mediated by the activation of PI3K/Akt/mTOR and activation of NF-κB, and requires GHS-R1a.http://dx.doi.org/10.1155/2019/9627810
spellingShingle Attalla Farag El-kott
Ali A. Shati
Mohammed Ali Al-kahtani
Sultan Alqahtani
Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway
Analytical Cellular Pathology
title Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway
title_full Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway
title_fullStr Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway
title_full_unstemmed Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway
title_short Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway
title_sort acylated ghrelin renders chemosensitive ovarian cancer cells resistant to cisplatin chemotherapy via activation of the pi3k akt mtor survival pathway
url http://dx.doi.org/10.1155/2019/9627810
work_keys_str_mv AT attallafaragelkott acylatedghrelinrenderschemosensitiveovariancancercellsresistanttocisplatinchemotherapyviaactivationofthepi3kaktmtorsurvivalpathway
AT aliashati acylatedghrelinrenderschemosensitiveovariancancercellsresistanttocisplatinchemotherapyviaactivationofthepi3kaktmtorsurvivalpathway
AT mohammedalialkahtani acylatedghrelinrenderschemosensitiveovariancancercellsresistanttocisplatinchemotherapyviaactivationofthepi3kaktmtorsurvivalpathway
AT sultanalqahtani acylatedghrelinrenderschemosensitiveovariancancercellsresistanttocisplatinchemotherapyviaactivationofthepi3kaktmtorsurvivalpathway